Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.

Their Wellcome Trust funded study, published in Nature Microbiology could spell disaster for patients with aspergillosis - a dangerous fungal disease responsible ... However, a newly developed ...